Privia Health Group, Inc.
PRVA
$18.56
$0.5052.80%
| Weiss Ratings | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | C- | |||
| Rating Factors | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.55 | |||
| Price History | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.88% | |||
| 30-Day Total Return | -20.76% | |||
| 60-Day Total Return | -21.98% | |||
| 90-Day Total Return | -18.89% | |||
| Year to Date Total Return | -24.84% | |||
| 1-Year Total Return | -32.45% | |||
| 2-Year Total Return | -30.15% | |||
| 3-Year Total Return | -48.72% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -40.13% | |||
| 52-Week Low % Change | 2.91% | |||
| Price | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $30.15 | |||
| 52-Week Low Price | $17.54 | |||
| 52-Week Low Price (Date) | Apr 02, 2024 | |||
| 52-Week High Price (Date) | May 09, 2023 | |||
| Valuation | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.15B | |||
| Enterprise Value | 1.81B | |||
| Price/Earnings (TTM) | 94.17 | |||
| Earnings Per Share (TTM) | 0.19 | |||
| Earnings Per Share Growth | -271.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.36 | |||
| Price/Book (Q) | 3.81 | |||
| Enterprise Value/Revenue (TTM) | 1.09 | |||
| Price | $17.82 | |||
| Enterprise Value/EBITDA (TTM) | 66.46 | |||
| Enterprise Value/EBIT | 87.48 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 124.83M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 571 366 8850 | |||
| Address | 950 North Glebe Road Arlington, VA 22203 | |||
| Website | www.priviahealth.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 1.24% | |||
| Profit Margin | 1.39% | |||
| Management Effectiveness | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 1.44% | |||
| Return on Equity | 3.73% | |||
| Income Statement | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.66B | |||
| Total Revenue (TTM) | 1.66B | |||
| Revenue Per Share | $13.28 | |||
| Gross Profit (TTM) | 161.50M | |||
| EBITDA (TTM) | 27.18M | |||
| EBIT (TTM) | 20.65M | |||
| Net Income (TTM) | 23.08M | |||
| Net Income Avl. to Common (TTM) | 23.08M | |||
| Total Revenue Growth (Q YOY) | 20.97% | |||
| Earnings Growth (Q YOY) | -86.21% | |||
| EPS Diluted (TTM) | 0.19 | |||
| EPS Diluted Growth (Q YOY) | -82.89% | |||
| Balance Sheet | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 389.51M | |||
| Cash Per Share (Q) | $3.12 | |||
| Total Current Assets (Q) | 700.80M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 607.39M | |||
| Current Ratio (Q) | 1.811 | |||
| Book Value Per Share (Q) | $4.75 | |||
| Total Assets (Q) | 999.90M | |||
| Total Current Liabilities (Q) | 386.95M | |||
| Total Debt (Q) | 8.29M | |||
| Total Liabilities (Q) | 392.51M | |||
| Total Common Equity (Q) | 561.44M | |||
| Cash Flow | PRVA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -42.97M | |||
| Cash from Financing (TTM) | 3.71M | |||
| Net Change in Cash (TTM) | 41.52M | |||
| Levered Free Cash Flow (TTM) | 71.75M | |||
| Cash from Operations (TTM) | 80.79M | |||
